These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 39036962)
1. PARP inhibitor therapy in patients with IDH1 mutated cholangiocarcinoma. Mohan A; Quingalahua E; Gunchick V; Paul S; Kumar-Sinha C; Crysler O; Zalupski MM; Sahai V Oncologist; 2024 Aug; 29(8):725-730. PubMed ID: 39036962 [TBL] [Abstract][Full Text] [Related]
2. Platinum sensitivity in patients with IDH1/2 mutated vs wild-type intrahepatic cholangiocarcinoma: A propensity score-based study. Niger M; Nichetti F; Casadei-Gardini A; Rizzato MD; Pircher C; Bini M; Franza A; Rimini M; Burgio V; Sposetti C; Fornaro L; Rapposelli IG; D'Amico FE; Aprile G; Vivaldi C; Frassineti GL; Milione M; Leoncini G; Cappetta A; Vasile E; Fassan M; Morano F; Perrone F; Tamborini E; Pruneri G; Lonardi S; Mazzaferro V; Pietrantonio F; Di Bartolomeo M; de Braud F Int J Cancer; 2022 Oct; 151(8):1310-1320. PubMed ID: 35723131 [TBL] [Abstract][Full Text] [Related]
3. Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients. Rimini M; Fabregat-Franco C; Persano M; Burgio V; Bergamo F; Niger M; Scartozzi M; Rapposelli IG; Aprile G; Ratti F; Pedica F; Verdaguer H; Rizzato M; Nichetti F; Lai E; Cappetta A; Macarulla T; Fassan M; De Braud F; Pretta A; Simionato F; De Cobelli F; Aldrighetti L; Fornaro L; Cascinu S; Casadei-Gardini A Target Oncol; 2023 Jan; 18(1):139-145. PubMed ID: 36689074 [TBL] [Abstract][Full Text] [Related]
4. Impact of IDH1 mutation on clinical course of patients with intrahepatic cholangiocarcinoma: a retrospective analysis from a German tertiary center. Kinzler MN; Jeroch J; Klasen C; Himmelsbach V; Koch C; Finkelmeier F; Trojan J; Zeuzem S; Pession U; Reis H; Demes MC; Wild PJ; Walter D J Cancer Res Clin Oncol; 2023 Aug; 149(9):6391-6398. PubMed ID: 36757619 [TBL] [Abstract][Full Text] [Related]
5. Comprehensive Immunogenomic Profiling of Makawita S; Lee S; Kong E; Kwong LN; Abouelfetouh Z; Danner De Armas A; Xiao L; Murugesan K; Danziger N; Pavlick D; Korkut A; Ross JS; Javle M JCO Precis Oncol; 2024 Mar; 8():e2300544. PubMed ID: 38547421 [TBL] [Abstract][Full Text] [Related]
9. PARP inhibitor plus radiotherapy reshape the immune suppressive microenvironment and potentiate the efficacy of immune checkpoint inhibitors in tumors with IDH1 mutation. Hu X; Zhao M; Bai M; Xue Z; Wang F; Zhu Z; Yu J; Yue J Cancer Lett; 2024 Apr; 586():216676. PubMed ID: 38278469 [TBL] [Abstract][Full Text] [Related]
10. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer. Tattersall A; Ryan N; Wiggans AJ; Rogozińska E; Morrison J Cochrane Database Syst Rev; 2022 Feb; 2(2):CD007929. PubMed ID: 35170751 [TBL] [Abstract][Full Text] [Related]
11. Mutation of Su L; Zhang X; Zheng L; Wang M; Zhu Z; Li P Front Endocrinol (Lausanne); 2020; 11():189. PubMed ID: 32373065 [No Abstract] [Full Text] [Related]
12. IDH1 as a frequently mutated gene has potential effect on exosomes releasement by epigenetically regulating P2RX7 in intrahepatic cholangiocarcinoma. Zhang X; Miao R; Liu T; Xiang X; Gu J; Jia Y; Li Z; Fu Y; He Y; Zhang Y; Zhang J; Qu K; Liu C Biomed Pharmacother; 2019 May; 113():108774. PubMed ID: 30889491 [TBL] [Abstract][Full Text] [Related]
13. Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma. Borger DR; Goyal L; Yau T; Poon RT; Ancukiewicz M; Deshpande V; Christiani DC; Liebman HM; Yang H; Kim H; Yen K; Faris JE; Iafrate AJ; Kwak EL; Clark JW; Allen JN; Blaszkowsky LS; Murphy JE; Saha SK; Hong TS; Wo JY; Ferrone CR; Tanabe KK; Bardeesy N; Straley KS; Agresta S; Schenkein DP; Ellisen LW; Ryan DP; Zhu AX Clin Cancer Res; 2014 Apr; 20(7):1884-90. PubMed ID: 24478380 [TBL] [Abstract][Full Text] [Related]
14. Crispo F; Pietrafesa M; Condelli V; Maddalena F; Bruno G; Piscazzi A; Sgambato A; Esposito F; Landriscina M Molecules; 2020 Aug; 25(16):. PubMed ID: 32824685 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of poly (ADP-ribose) polymerase inhibitors monotherapy and the impact to subsequent platinum-based chemotherapy in breast cancer susceptibility genes1/2-mutated ovarian cancer patients with secondary platinum-sensitive relapse. Ma Y; Liu J; Li N; Bu H; Huang Y; Jin C; Wen H; Feng S; Zhang H; Yang X; Kong B; Wu L; Song K J Ovarian Res; 2023 Oct; 16(1):209. PubMed ID: 37891662 [TBL] [Abstract][Full Text] [Related]
16. Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase-mutated intrahepatic cholangiocarcinomas. Delahousse J; Verlingue L; Broutin S; Legoupil C; Touat M; Doucet L; Ammari S; Lacroix L; Ducreux M; Scoazec JY; Malka D; Paci A; Hollebecque A Eur J Cancer; 2018 Feb; 90():83-91. PubMed ID: 29274619 [TBL] [Abstract][Full Text] [Related]
17. Intrahepatic cholangiocarcinomas with IDH1/2 mutation-associated hypermethylation at selective genes and their clinicopathological features. Lee K; Song YS; Shin Y; Wen X; Kim Y; Cho NY; Bae JM; Kang GH Sci Rep; 2020 Sep; 10(1):15820. PubMed ID: 32978444 [TBL] [Abstract][Full Text] [Related]